124 related articles for article (PubMed ID: 26397239)
21. Diagnosis and treatment of follicular lymphoma: an update.
Bargetzi M; Baumann R; Cogliatti S; Dietrich PY; Duchosal M; Goede J; Hitz F; Konermann C; Lohri A; Mey U; Novak U; Papachristofilou A; Stenner F; Taverna C; Zander T; Renner C
Swiss Med Wkly; 2018; 148():w14635. PubMed ID: 30044476
[TBL] [Abstract][Full Text] [Related]
22. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
[No Abstract] [Full Text] [Related]
23. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
24. Follicular lymphoma of the ocular adnexal region: a nation-based study.
Rasmussen PK; Ralfkiaer E; Prause JU; Sjö LD; Specht L; Rossing HH; Siersma VD; Heegaard S
Acta Ophthalmol; 2015 Mar; 93(2):184-91. PubMed ID: 25125069
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
26. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
28. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
29. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.
Zinzani PL; Marchetti M; Billio A; Barosi G; Carella AM; Lazzarino M; Martelli M; Rambaldi A; Rigacci L; Tarella C; Vitolo U; Tura S;
Am J Hematol; 2013 Mar; 88(3):185-92. PubMed ID: 23339086
[TBL] [Abstract][Full Text] [Related]
30. Clinical features, prognosis and treatment of follicular lymphoma.
Salles GA
Hematology Am Soc Hematol Educ Program; 2007; ():216-25. PubMed ID: 18024633
[TBL] [Abstract][Full Text] [Related]
31. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
32. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
Am J Hematol; 2016 Jun; 91(6):E305-7. PubMed ID: 26950187
[No Abstract] [Full Text] [Related]
33. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
34. A treated case of follicular lymphoma presenting with fever and diarrhea.
Vaiphei K; Malhotra P; Sharma N; Narasiyappah AK; Varma SC
Indian J Gastroenterol; 2007; 26(5):240-3. PubMed ID: 18227577
[No Abstract] [Full Text] [Related]
35. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
[TBL] [Abstract][Full Text] [Related]
36. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
37. [Up-to-date treatment of follicular lymphomas].
Dreyling M; Buske C; Hiddemann W
Dtsch Med Wochenschr; 2005 Sep; 130(38):2149-54. PubMed ID: 16172957
[No Abstract] [Full Text] [Related]
38. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
39. Rituximab maintenance or retreatment after autologous transplantation for relapsed follicular lymphoma?
Fozza C
J Clin Oncol; 2013 Oct; 31(30):3846-7. PubMed ID: 24062390
[No Abstract] [Full Text] [Related]
40. First-line obinutuzumab for follicular lymphoma.
Baker H
Lancet Oncol; 2017 Nov; 18(11):e648. PubMed ID: 29033196
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
